Cefoxitin: synergism with aminoglycosides in vitro

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Antibiotic resistance is a growing global health concern.
• Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus are common causes of hospital-acquired infections.
• Cefoxitin and aminoglycosides are classes of antibiotics used to treat bacterial infections.

Purpose of the Study:

• To investigate the in vitro synergistic effects of cefoxitin in combination with various aminoglycosides.
• To evaluate the efficacy of this combination against clinical isolates of Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus.
• To explore potential mechanisms for observed synergistic interactions.

Main Methods:

• Testing the in vitro synergistic effect of cefoxitin combined with gentamicin, tobramycin, amikacin, and dibekacin.
• Utilizing fresh clinical isolates: 15 Escherichia coli, 15 Staphylococcus aureus, and 105 Pseudomonas aeruginosa.
• Assessing bacterial susceptibility to the antibiotic combination.

Main Results:

• Distinct synergy was observed between cefoxitin and aminoglycosides against numerous Pseudomonas aeruginosa strains, particularly those highly resistant to cefoxitin monotherapy.
• The combination demonstrated a lack of synergistic effect against strains of Escherichia coli and Staphylococcus aureus.
• A discussion on the potential in vitro synergistic mechanisms against Pseudomonas aeruginosa was included.

Conclusions:

• The combination of cefoxitin and aminoglycosides presents a promising synergistic approach for treating Pseudomonas aeruginosa infections, especially in cases of high cefoxitin resistance.
• This combination therapy is not effective against Escherichia coli and Staphylococcus aureus.
• Further research into the mechanisms of synergy against P. aeruginosa is warranted.